Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors
This study will evaluate dose escalation of melatonin in pediatric oncology patients with relapsed solid tumors. The purpose of this study is to determine the safety of melatonin at a dose up to 20 mg daily, as well as to determine the maximum tolerated dose of melatonin.
Relapsed Malignant Solid Tumor
DRUG: Melatonin
Maximum tolerated daily dose of melatonin., 8 Weeks
Number of dose limiting toxicities during 8 weeks of melatonin therapy., 8 Weeks|Peak plasma concentration (Cmax) and area under the plasma concentration versus time curve (AUC) of Melatonin., 8 Weeks|The quantity of cytokines will be measured during 8 weeks of melatonin therapy., 8 Weeks|Change from Baseline in weight after 8 weeks of therapy., 8 Weeks
This study will evaluate dose escalation of melatonin in pediatric oncology patients with relapsed solid tumors. The purpose of this study is to determine the safety of melatonin at a dose up to 20 mg daily, as well as to determine the maximum tolerated dose of melatonin.